Investigational drug · Phase 2
Danburstotug
Also called: IMC-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors, Extranodal NK/T-cell Lymphoma, Nasal Type.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Danburstotug"
First trial start
2020
Oct 27, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Danburstotug", any sponsor or status.
Conditions studied
As listed on its trial records.
- TMB-H
- Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
- Extranodal NK/T-cell Lymphoma, Nasal Type
- Extranodal NK/T-cell Lymphoma
Approved drugs for the same conditions: Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Danburstotug" as an intervention, largest first.
- A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeActive, not recruiting
ImmuneOncia Therapeutics Inc.Industry
NCT04414163 · 23 participants · Start Oct 27, 2020 · Primary completion Jul 23, 2024
Drug: IMC-001 · For: Extranodal NK/T-cell Lymphoma, Nasal Type; Extranodal NK/T-cell Lymphoma
Sites: Gwangju, South Korea; Seoul, South Korea; Ulsan, South Korea · 5 sites in all
Mayo ClinicAcademic, hospital or other
NCT05653661 · 0 participants · Start Jul 30, 2024 · Primary completion Jul 30, 2024
Drug: Nab-paclitaxel/Danburstotug Complex AP160 · For: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Melanoma
Sites: Rochester, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
- Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.
Kim WS, Kim SJ, Jo JC, et al. · Br J Haematol 2026
- Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study.
Bang YH, Kang D, Lee S, et al. · NPJ Precis Oncol 2026
- A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.
Keam B, Ock CY, Kim TM, et al. · Invest New Drugs 2021
- Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE, Kim SE, Keam B, et al. · J Immunother Cancer 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.